The goal of this activity is for learners to be better able to understand the biological and clinical rationale of new agents in prostate cancer, enhance clinicians ability to stay up to date with new and emerging data, and increase their awareness of adverse events associated with these therapies in an effort to elevate their confidence in implementing these therapies into practice.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1000819
- Start Date: 2024-05-15 05:00:00
- End Date: 2024-05-15 05:00:00
- Credit Details: IPCE Credits: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 66091.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest